Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new Parkinson's drug just got the green light. The FDA approved tavapadon (Juvmo), a once-daily oral dopamine D1/D5 receptor agonist made by AbbVie, for adults with Parkinson's disease. It can be used alone or alongside levodopa, offering a new option for patients with early-stage disease or those experiencing motor fluctuations. Expect it available in the U.S. by October 2026.
A new chapter in Parkinson's treatment. The FDA has approved tavapadon (brand name: Juvmo), a once-daily oral drug developed by AbbVie, for adults with Parkinson's disease. It's the first selective dopamine D1/D5 receptor agonist approved for PD — a distinct mechanism from existing dopamine agonists — and it can be used both as a standalone therapy in early-stage disease and as an add-on to levodopa for patients dealing with motor fluctuations.
The approval was backed by the phase 3 TEMPO clinical trial program, which ran three separate studies across different patient populations. Results were compelling across the board, with patients on tavapadon showing meaningful improvements in motor and daily functioning scores compared to placebo. AbbVie expects the drug to be commercially available in the U.S. by October 2026.
By the Numbers:
Why it matters: Parkinson's patients often struggle with motor fluctuations and side effects from existing therapies. Tavapadon's unique mechanism and flexible use — with or without levodopa — gives neurologists a meaningful new tool to personalize treatment and improve quality of life for patients at multiple stages of the disease.
